ABUS Arbutus Biopharma Corporation - Common Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 12, 2026
$4,45
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$3,67rendah 52m
$5,45tinggi 52m
Kapitalisasi Pasar (MRQ)
$879M
P/E (TTM)
5.6
EPS (TTM)
$0.79
Pendapatan (TTM)
$182M
lencana Anda
Rentang 52M
$4–$5
Peringkat Analis
STRONG BUY
Target Harga
$5
P/E
5.6
ROE
89.6%
Margin Laba Bersih
84.2%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
ABUS Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$4.45
Kapitalisasi Pasar (MRQ)
$879M
P/E (TTM)
5.6
EPS (TTM)
$0.79
Pendapatan (TTM)
$182M
ROE (TTM)
89.6%
Rentang 52M
$4–$5
ABUS Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Pemecahan saham
| Tanggal ex-dividen | Pemecahan | Tipe |
|---|---|---|
| 4 Nov. 2010 | 1-for-5 | Terbalik |
Tentang Arbutus Biopharma Corporation - Common Stock Tinjauan perusahaan dari Wikipedia
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
karyawan19
negaraCA
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$14M2016-12-31 → 2025-12-31
EPS$-0.172016-12-31 → 2025-12-31
Arus Kas Bebas$-40M2016-12-31 → 2025-12-31
Margin bersih84.2%2016-12-31 → 2025-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | ABUS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | 5.6rata-rata 5T ≈-10.5 | ≈-10.5 | · | · | |
| P/S (TTM) | 4.8rata-rata 5T ≈50.1 | ≈50.1 | 10.3 | Kurang nilai | |
| P/B (MRQ) | 3.4rata-rata 5T ≈5.7 | ≈5.7 | 3.7 | Nilai wajar | |
| Price / FCF (Harga / FCF) | -22.1rata-rata 5T ≈-11.3 | ≈-11.3 | · | · | |
| Price / Cash Flow (Harga / Arus Kas) | -22.1rata-rata 5T ≈-11.3 | ≈-11.3 | · | · | |
| Price / Tangible Book (Harga / Nilai Buku Berwujud) | 11.4rata-rata 5T ≈5.7 | ≈5.7 | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | ABUS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | 82.0%rata-rata 5T ≈-555.0% | ≈-555.0% | -588.2% | Sejajar | |
| EBITDA Margin (Margin EBITDA) | -271.0%rata-rata 5T ≈-555.0% | ≈-555.0% | -588.2% | Sejajar | |
| Margin Laba Bersih (TTM) | 84.2%rata-rata 5T ≈-528.9% | ≈-528.9% | -507.2% | Sejajar | |
| ROA (TTM) | 81.1%rata-rata 5T ≈-40.5% | ≈-40.5% | -29.6% | Sejajar | |
| ROE (TTM) | 89.6%rata-rata 5T ≈-55.0% | ≈-55.0% | -42.0% | Sejajar |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | ABUS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Rasio Lancar (MRQ) | 81.4rata-rata 5T ≈9.7 | ≈9.7 | 9.6 | Likuiditas kuat | |
| Quick Ratio (Rasio Cepat) | 15.5rata-rata 5T ≈9.5 | ≈9.5 | 6.6 | Sejajar |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | ABUS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 128.2%rata-rata 5T ≈64.5% | ≈64.5% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | -28.8%rata-rata 5T ≈-2.8% | ≈-2.8% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 15.3% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | ABUS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.1rata-rata 5T ≈0.1 | ≈0.1 | 0.2 | Lemah | |
| Receivables Turnover (Perputaran Piutang) | 7.3rata-rata 5T ≈13.3 | ≈13.3 | · | · | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$741.2K | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
581.5%
Laporan Berikutnya
Nov 11, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 4, 2026 | $-0.03 | $-0.02 | -47.1% |
| 31 Maret 2026 | Mei 12, 2026 | $1.19 | $-0.03 | 3988.9% |
| 31 Des. 2025 | $-0.02 | $-0.04 | 44.0% | |
| 30 Sep. 2025 | $-0.04 | $-0.03 | -26.6% | |
| 30 Juni 2025 | $0.01 | $-0.05 | 120.6% | |
| 31 Maret 2025 | $-0.13 | $-0.11 | -23.2% | |
| 31 Des. 2024 | $-0.07 | $-0.08 | 14.2% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.40 | $0.51 | $0.62 | $0.87 | $1.17 | $1.14 | · | $3.61 | $3.31 | $3.70 | · | |
| Revenue / Share | $0.07 | $0.03 | $0.11 | $0.26 | $0.10 | · | · | $0.11 | $0.20 | $0.03 | · | |
| Cash Flow / Share | $-0.21 | $-0.35 | $-0.52 | $-0.23 | $-0.64 | · | · | $-1.23 | $-0.89 | $-1.09 | · | |
| Cash / Share | $0.09 | $0.19 | $0.15 | $0.20 | $0.75 | $0.58 | · | $0.67 | $0.99 | $0.43 | · | |
| EPS (TTM) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | $-1.32 | $-1.21 | $-1.56 | $-7.24 | $-1.38 |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | · | 191,778,950 | 191,551,282 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | · | 191,778,950 | 192,399,733 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.31 | $1.32 | · | $0.40 | $0.43 | $0.41 | · | $0.56 | $0.65 | $0.64 | · | $0.71 | $0.81 | $0.87 | · | $0.95 | |
| Revenue / Share | $0.01 | $0.92 | · | $0.00 | $0.06 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.03 | $0.03 | $0.04 | · | $0.04 | |
| Cash Flow / Share | · | $-0.04 | · | · | · | $-0.07 | · | · | · | $-0.11 | · | · | · | $-0.17 | · | · | |
| Cash / Share | $0.10 | $0.12 | · | $0.12 | $0.20 | $0.19 | · | $0.17 | $0.33 | $0.24 | · | $0.10 | $0.16 | $0.25 | · | $0.16 | |
| EPS (TTM) | $0.79 | $0.83 | · | $-0.23 | $-0.29 | $-0.41 | · | $-0.43 | $-0.45 | $-0.44 | · | $-0.45 | $-0.45 | $-0.45 | · | $-0.48 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $182M | $191M | · | $15M | $15M | $6M | · | $7M | $10M | $13M | · | $22M | $24M | $33M | · | $36M | |
| Net Income TTM | $153M | $161M | · | $-42M | $-54M | $-77M | · | $-77M | $-77M | $-74M | · | $-75M | $-73M | $-70M | · | $-69M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 6.1 | 5.4 | · | -19.7 | -10.7 | -8.5 | · | -9.0 | -6.9 | -5.9 | · | -4.5 | -5.1 | -6.7 | · | -4.0 | |
| P/S | 5.2 | 4.6 | · | 59.7 | 38.4 | 104.4 | · | 108.2 | 58.0 | 35.8 | · | 15.3 | 16.3 | 15.1 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| Earnings Yield | 16.5% | 18.4% | · | -5.1% | -9.4% | -11.8% | · | -11.2% | -14.6% | -17.1% | · | -22.2% | -19.6% | -14.8% | · | -25.1% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $14M | $6M | $18M | $39M | $11M |
| Margin Operasi % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Laba Bersih | $-34M | $-70M | $-73M | $-69M | $-76M |
| EPS Dilusian | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rasio Lancar | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| Rasio Cepat | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-40M | $-65M | $-87M | $-36M | $-68M |
Pemilik institusional (13F) 187 pengaju · $719.6M total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
187
Nilai yang dipegang
$719.6M
Posisi baru
35
Posisi yang keluar
23
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 35 (+3 vs Kuartal sebelumnya) | 23 (-8 vs Kuartal sebelumnya) | 62 (+13 vs Kuartal sebelumnya) | 42 (-10 vs Kuartal sebelumnya) | +466K |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| Two Seas Capital LP | $91.658.798 | 19.095.583 | 12,74% | Saham |
| MORGAN STANLEY | $84.951.868 | 17.698.305 | 11,81% | Saham |
| Whitefort Capital Management, LP | $75.812.453 | 15.794.261 | 10,54% | Saham |
| BlackRock, Inc. | $66.077.140 | 13.766.071 | 9,18% | Saham |
| VANGUARD GROUP INC | $44.456.122 | 9.242.437 | 6,18% | Saham |
| STATE STREET CORP | $37.772.059 | 7.869.179 | 5,25% | Saham |
| Rubric Capital Management LP | $36.158.098 | 7.532.937 | 5,03% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $33.651.259 | 7.010.679 | 4,68% | Saham |
| BARCLAYS PLC | $20.197.987 | 4.207.914 | 2,81% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $19.769.043 | 4.117.691 | 2,75% | Saham |
| GOLDMAN SACHS GROUP INC | $16.832.650 | 3.506.802 | 2,34% | Saham |
| BANK OF AMERICA CORP /DE/ | $12.701.745 | 2.646.197 | 1,77% | Saham |
| BlackBarn Capital Partners LP | $12.000.000 | 2.500.000 | 1,67% | Saham |
| Legal & General Group Plc | $11.837.409 | 2.466.127 | 1,65% | Saham |
| Woodline Partners LP | $10.952.909 | 2.281.856 | 1,52% | Saham |
| Jefferies Financial Group Inc. | $8.216.026 | 1.711.672 | 1,14% | Saham |
| NOMURA HOLDINGS INC | $7.857.989 | 1.637.081 | 1,09% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7.398.998 | 1.541.458 | 1,03% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6.869.846 | 1.431.218 | 0,95% | Saham |
| NORTHERN TRUST CORP | $6.811.315 | 1.419.024 | 0,95% | Saham |
| OSAIC HOLDINGS, INC. | $6.469.756 | 1.347.866 | 0,90% | Saham |
| ADAR1 Capital Management, LLC | $6.087.106 | 1.268.147 | 0,85% | Saham |
| Deltroit Asset Management (UK) LLP | $5.760.000 | 1.200.000 | 0,80% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $5.449.738 | 1.135.362 | 0,76% | Saham |
| CITIGROUP INC | $4.220.338 | 879.237 | 0,59% | Saham |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3.771.945 | 838.210 | 0,52% | Saham |
| BANK OF MONTREAL /CAN/ | $3.734.102 | 777.938 | 0,52% | Saham |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3.123.360 | 650.700 | 0,43% | Saham |
| MACKENZIE FINANCIAL CORP | $2.946.269 | 613.806 | 0,41% | Saham |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2.889.638 | 602.008 | 0,40% | Saham |
| Western Standard LLC | $2.605.378 | 542.787 | 0,36% | Saham |
| Rangeley Capital, LLC | $2.400.000 | 500.000 | 0,33% | Saham |
| Nuveen, LLC | $2.383.723 | 496.609 | 0,33% | Saham |
| Man Group plc | $2.272.642 | 473.467 | 0,32% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $2.215.900 | 461.646 | 0,31% | Saham |
| Bank of New York Mellon Corp | $2.179.752 | 454.115 | 0,30% | Saham |
| CenterBook Partners LP | $2.136.725 | 445.151 | 0,30% | Saham |
| Freestone Capital Holdings, LLC | $2.124.000 | 442.500 | 0,30% | Saham |
| CITADEL ADVISORS LLC | $1.942.541 | 404.696 | 0,27% | Saham |
| KENNEDY CAPITAL MANAGEMENT LLC | $1.849.430 | 385.298 | 0,26% | Saham |
| D. E. Shaw & Co., Inc. | $1.832.942 | 381.863 | 0,25% | Saham |
| Swiss National Bank | $1.375.200 | 286.500 | 0,19% | Saham |
| Ledgewood Wealth Advisors, LLC | $1.336.493 | 278.436 | 0,19% | Saham |
| FMR LLC | $1.282.503 | 267.188 | 0,18% | Saham |
| Susquehanna Portfolio Strategies, LLC | $1.265.688 | 263.685 | 0,18% | Saham |
| Carrera Capital Advisors | $1.234.402 | 257.167 | 0,17% | Saham |
| Quinn Opportunity Partners LLC | $1.225.027 | 255.214 | 0,17% | Saham |
| Invesco Ltd. | $1.204.353 | 250.907 | 0,17% | Saham |
| UBS Group AG | $1.196.198 | 249.208 | 0,17% | Saham |
| STATE OF WISCONSIN INVESTMENT BOARD | $1.161.682 | 242.017 | 0,16% | Saham |
Aktivis & pemilik 5%+ 8 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 pengajuan | 28 April 2026 | 8,00% | Amandemen | · | SEC |
| Roivant Sciences Ltd. ×14 pengajuan | 25 Feb. 2025 | 20,50% | Amandemen | · | SEC |
| Patrick Machado ×4 pengajuan | 17 Juli 2019 | · | Pengajuan awal | · | SEC |
| Dr. Andrew Lo ×5 pengajuan | 17 Juli 2019 | · | Pengajuan awal | · | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 pengajuan | 12 Juli 2019 | · | Pengajuan awal | · | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 pengajuan | 12 Juli 2019 | · | Pengajuan awal | · | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 pengajuan | 12 Juli 2019 | · | Pengajuan awal | · | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 pengajuan | 12 Juli 2019 | · | Pengajuan awal | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 35 orang dalam · 17 pejabat · 19 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Lindsay Androski | President and CEO | 18 Sep. 2026 M | 72.337 | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Interim President & CEO | 14 Feb. 2025 A | 1.658.003 | 0 | 0 | $0 |
| William H. Collier | President and CEO | 1 Feb. 2023 A | 216.500 | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 1 Maret 2019 A | 341.396 | 0 | 0 | $0 |
| Tuan Nguyen | Chief Financial Officer | 18 Sep. 2026 M | 159.963 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 14 Feb. 2025 A | 249.824 | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 24 Maret 2017 A | · | 0 | 0 | $0 |
| Karen Sims | Chief Medical Officer | 14 Feb. 2025 A | 155.494 | 0 | 0 | $0 |
| Christopher J. Naftzger | General Counsel and CCO | 14 Feb. 2025 A | 140.544 | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 1 Feb. 2024 A | 1.485.121 | 0 | 0 | $0 |
| Elizabeth Howard | EVP, GC, Compliance | 1 Feb. 2023 A | 86.024 | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 20 Jan. 2022 A | · | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 11 Des. 2018 A | · | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 16 April 2018 A | · | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 24 Maret 2017 A | · | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 16 Agu 2016 M | 42.097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 15 Maret 2016 A | · | 0 | 0 | $0 |
| Roger Sawhney | Direktur | 18 Sep. 2026 M | 30.825 | 0 | 0 | $0 |
| Robert A Beardsley | Direktur | 18 Sep. 2026 M | 32.276 | 0 | 0 | $0 |
| Anuj Hasija | Direktur | 18 Maret 2025 A | · | 0 | 0 | $0 |
| Keith S Manchester | Direktur | 14 Agu 2024 M | 46.069 | 0 | 0 | $0 |
| Melissa Rewolinski | Direktur | 23 Mei 2024 A | · | 0 | 0 | $0 |
| Frank Torti | Direktur | 23 Mei 2024 A | · | 0 | 0 | $0 |
| James R Meyers | Direktur | 23 Mei 2024 A | · | 0 | 0 | $0 |
| Daniel D Burgess | Direktur | 23 Mei 2024 A | · | 0 | 0 | $0 |
| Richard C Henriques JR | Direktur | 23 Mei 2024 A | 1.000 | 0 | 0 | $0 |
| Tram Tran | Direktur | 25 Mei 2022 A | · | 0 | 0 | $0 |
| Andrew Cheng | Direktur | 3 Juni 2021 A | · | 0 | 0 | $0 |
| Myrtle S Potter | Direktur | 17 Agu 2019 A | · | 0 | 0 | $0 |
| Vivek Ramaswamy | Direktur | 19 Juni 2018 A | · | 0 | 0 | $0 |
| Herbert J Conrad | Direktur | 19 Juni 2018 A | · | 0 | 0 | $0 |
| Frank Karbe | Direktur | 21 Juni 2017 A | · | 0 | 0 | $0 |
| Roivant Sciences Ltd. | Pemilik 10% | 18 Okt. 2021 C | 38.847.462 | 0 | 0 | $0 |
| Andrew Lo | Pemilik 10% | 12 Jan. 2018 P | · | 0 | 0 | $0 |
| Patrick Machado | Pemilik 10% | 12 Jan. 2018 P | · | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 26 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,68% | 72.962 NS | 31 Juli 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 521.191 NS | 31 Juli 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,47% | 23.611 SH | 2 Okt. 2026 | Harian |
| IWC · iShares Trust | 0,19% | 545.721 SH | 11 Sep. 2026 | Harian |
| LABU · Direxion Shares ETF Trust | 0,11% | 124.896 NS | 31 Juli 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,06% | 14.124 SH | 2 Okt. 2026 | Harian |
| IBB · iShares Trust | 0,06% | 1.201.130 SH | 11 Sep. 2026 | Harian |
| IWO · iShares Trust | 0,05% | 1.506.889 SH | 11 Sep. 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,05% | 172.487 SH | 19 Agu 2026 | Harian |
| PWS · Pacer Funds Trust | 0,03% | 1.706 NS | 31 Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,03% | 4.035.105 SH | 11 Sep. 2026 | Harian |
| RSSL · Global X Funds | 0,02% | 76.843 NS | 31 Juli 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 120.110 SH | 2 Okt. 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 925.044 SH | 19 Agu 2026 | Harian |
| ISCG · iShares Trust | 0,01% | 24.707 SH | 11 Sep. 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1.810.587 SH | 19 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,01% | 430.244 SH | 19 Agu 2026 | Harian |
| WSML · iShares Trust | 0,01% | 11.624 SH | 9 Sep. 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 66.333 NS | 31 Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 265.986 SH | 11 Sep. 2026 | Harian |
| IWV · iShares Trust | 0,00% | 49.783 SH | 9 Sep. 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.034.547 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13.683 SH | 19 Agu 2026 | Harian |
| ISCB · iShares Trust | · | 6.673 SH | 11 Sep. 2026 | Harian |
| ISCV · iShares Trust | · | 13.314 SH | 11 Sep. 2026 | Harian |
| SMMV · iShares Trust | · | 60.845 SH | 1 Sep. 2026 | Harian |
ABUS Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 7 analis
BELI
Target median
$5.39
+21,0%
3 42,9%
Beli Kuat
3 42,9%
Beli
1 14,3%
Tahan
0 0,0%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
1 analis · 2026-09-28Target rata-rata $5.39 +21,0%
Rendah$5.39
Rata-rata$5.39
Tinggi$5.39
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 12, 2026